Geert Kleinnibbelink

Chapter 8 178 0 0 30 25 20 15 10 5 -2 35 -4 -6 -8 -10 -12 -14 -16 -18 baseline systolic baseline diastolic follow-up systolic follow-up diastolic 0 0 30 25 20 15 10 5 -2 -4 -6 -8 -10 -12 -14 -16 -18 baseline systolic baseline diastolic follow-up systolic follow-up diastolic 0 0 30 25 20 15 10 5 -2 35 -4 -6 -8 -10 -12 -14 -16 -18 baseline systolic baseline diastolic follow-up systolic follow-up diastolic A) B) C) RV longitudinal strain (%) RV longitudinal strain (%) RV longitudinal strain (%) RV area (cm 2 ) RV area (cm 2 ) RV area (cm 2 ) Figure 1 . Mean RV strain-area loop of (A) all participants (n=8) (Uncoupling 1.3±0.7 to 1.1±1.3, p=0.81; Uncoupling ED 1.3±0.8 to 1.1±1.4, p=0.66; Uncoupling LD 1.2±0.5 to 1.3±1.2, p=0.73; Sslope 1.6±0.4 to 1.8±0.7, p=0.21), (B) clinical responders (n=3) (Uncoupling 1.3±0.7 to 1.9±1.1, p=0.56; Uncoupling ED 1.2±0.8 to 1.8±1.3, p=0.64; Uncoupling LD 1.3±0.5 to 2.0±0.6, p=0.34; Sslope 1.8±0.5 to 1.9±0.7, p=0.20), and (C) clinical non- responders (n=5) (Uncoupling 1.3±0.7 to 0.7±1.3, p=0.42; Uncoupling ED 1.4±0.8 to 0.6±1.3, p=0.32; Uncoupling LD 1.1±0.6 to 0.9±1.3, p=0.78; Sslope 1.4±0.2 to 1.7±0.7, p=0.36) at baseline and following 17-weeks of treatment with Selexipag.